ReviewMedicine2013
Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature.
Review in Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review.Rheumatology international · 2026Pooled it
- Article
- Development and Validation of the PASS Score: A Simplified Tool to Diagnose Acquired Aplastic Anemia in Adults.Research square · 2026Article
- Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report.Clinical case reports · 2026Article
- Current view on the etiopathogenesis of aplastic anemia.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Review
- A difficult diagnosis of eosinophilic fasciitis: A case report.SAGE open medical case reports · 2024Article
- Is there a Role for Anti-IL-5 Therapies in Eosinophilic Fasciitis?Mediterranean journal of rheumatology · 2023Review
- Clinical characteristics and risk factors of patients with eosinophilic fasciitis associated with pleural effusion.Scientific reports · 2023Article
- Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature.Mediterranean journal of rheumatology · 2023Review
- Article
- Hypercellular bone marrow in aplastic anemia: A case report of two patients.Clinical case reports · 2021Article
- Case 31-2021: A 21-Year-Old Man with Sore Throat, Epistaxis, and Oropharyngeal Petechiae.The New England journal of medicine · 2021Article
- Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review.Rheumatology international · 2021Review
- Eosinophilic fasciitis in a pregnant woman with corticosteroid dependence and good response to infliximab.Rheumatology international · 2021Article
- Distinguishing constitutional from acquired bone marrow failure in the hematology clinic.Best practice & research. Clinical haematology · 2021Review
- Aplastic anemia in a patient with CVID due to NFKB1 haploinsufficiency.Cold Spring Harbor molecular case studies · 2020Article
- The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review.Clinical rheumatology · 2020Review
- Article
- A Histologically Proven Case of Autoimmune Hepatitis with Eosinophilic Fasciitis.Internal medicine (Tokyo, Japan) · 2019Article
- Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment.Current rheumatology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse eosinophilic fasciitis (Shulman disease) is a rare sclerodermiform syndrome that, in most cases, resolves spontaneously or after corticosteroid therapy. It has been associated with hematologic disorders, such as aplastic anemia. The clinical features and long-term outcomes of patients with eosinophilic fasciitis and associated aplastic anemia have been poorly described. We report the cases of 4 patients with eosinophilic fasciitis and associated severe aplastic anemia. For 3 of these patients, aplastic anemia was refractory to conventional immunosuppressive therapy with antithymocyte globulin and cyclosporine. One of the patients received rituximab as a second-line therapy with significant efficacy for both the skin and hematologic symptoms. To our knowledge, this report is the first to describe rituximab used to treat eosinophilic fasciitis with associated aplastic anemia. In a literature review, we identified 19 additional cases of eosinophilic fasciitis and aplastic anemia. Compared to patients with isolated eosinophilic fasciitis, patients with eosinophilic fasciitis and associated aplastic anemia were more likely to be men (70%) and older (mean age, 56 yr; range, 18-71 yr). Corticosteroid-containing regimens improved skin symptoms in 5 (42%) of 12 cases but were ineffective in the treatment of associated aplastic anemia in all but 1 case. Aplastic anemia was profound in 13 cases (57%) and was the cause of death in 8 cases (35%). Only 5 patients (22%) achieved long-term remission (allogeneic hematopoietic stem cell transplantation: n = 2; cyclosporine-containing regimen: n = 2; high-dose corticosteroid-based regimen: n = 1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.